574 related articles for article (PubMed ID: 12579325)
21. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.
Mikysková R; Bubenik J; Mendoza L; Vonka V; Smahel M; Símová J; Jandlová T
Clin Exp Metastasis; 2000; 18(7):581-7. PubMed ID: 11688963
[TBL] [Abstract][Full Text] [Related]
22. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
[TBL] [Abstract][Full Text] [Related]
23. NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours.
Indrová M; Símová J; Bieblová J; Bubeník J; Reinis M
Oncol Rep; 2011 Jan; 25(1):281-8. PubMed ID: 21109988
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells.
Sobotkova E; Duskova M; Eckschlager T; Vonka V
Int J Oncol; 2008 Aug; 33(2):421-6. PubMed ID: 18636165
[TBL] [Abstract][Full Text] [Related]
25. Antitumor Effect on Murine Renal Cell Carcinoma by Autologous Tumor Vaccines Genetically Modified with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-6 Cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother (1991); 2001 May; 24(3):205-211. PubMed ID: 11395635
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells.
Qin Z; Noffz G; Mohaupt M; Blankenstein T
J Immunol; 1997 Jul; 159(2):770-6. PubMed ID: 9218594
[TBL] [Abstract][Full Text] [Related]
27. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
28. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
[TBL] [Abstract][Full Text] [Related]
29. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
Lichtor T; Glick RP; Lin H; O-Sullivan I; Cohen EP
Cancer Gene Ther; 2005 Aug; 12(8):708-14. PubMed ID: 15803143
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy with tumor vaccine increases the survival of hepatoma-bearing mice.
Chao Y; Shih YL; Cheng HJ; Wei SJ; Chi KH; Yeh SH; Lee SD; Yang WK
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):682-9. PubMed ID: 10533297
[TBL] [Abstract][Full Text] [Related]
32. Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response.
Lee SG; Heo DS; Yoon SJ; Jee YS; Kang JO; Kim K; Kim CD; Sung MW; Kim NK
Anticancer Res; 2000; 20(4):2681-6. PubMed ID: 10953343
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
34. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
[TBL] [Abstract][Full Text] [Related]
35. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
36. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule.
Lu Y; Yamauchi N; Koshita Y; Fujiwara H; Sato Y; Fujii S; Takahashi M; Sato T; Kato J; Yamagishi H; Niitsu Y
Gene Ther; 2001 Apr; 8(7):499-507. PubMed ID: 11319616
[TBL] [Abstract][Full Text] [Related]
37. Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2.
Jinoch P; Zak R; Janousková O; Kunke D; Rittich S; Duskova M; Sobotkova E; Marinov I; Andelova M; Smahel M; Vonka V
Int J Oncol; 2003 Sep; 23(3):775-83. PubMed ID: 12888917
[TBL] [Abstract][Full Text] [Related]
38. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity.
Aruga A; Tanigawa K; Aruga E; Yu H; Chang AE
Cancer Gene Ther; 1999; 6(1):89-95. PubMed ID: 10078968
[TBL] [Abstract][Full Text] [Related]
39. Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells.
Lechanteur C; Moutschen M; Princen F; Lopez M; Franzen E; Gielen J; Bours V; Merville MP
Cancer Gene Ther; 2000 May; 7(5):676-82. PubMed ID: 10830715
[TBL] [Abstract][Full Text] [Related]
40. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]